Autologous bone marrow-derived mesenchymal stem cell transplantation promotes liver regeneration after portal vein embolization in cirrhotic rats

Li, Tingjun; Zhu, Jun; Ma, Kui; Liu, Nianzhou; Feng, Kai; Li, Xiaowu; Wang, Shuguang; Bie, Ping

doi:10.1016/j.jss.2013.04.054

Cited by 39 publications

(38 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HGF has a vital role in liver regeneration [4] and exerts an anti-fibrotic effect by inhibiting the expression of collagen and TGF-β1, thereby repressing the activity of HSCs [6]. Consistent with the findings of Li et al [25], the present study revealed that both intravenous and intrasplenic administration of BM-MSCs had similar effects in increasing CK18 and HGF gene expression.…”

Section: Discussionsupporting

confidence: 91%

Treatment Efficiency of Different Routes of Bone Marrow-Derived Mesenchymal Stem Cell Injection in Rat Liver Fibrosis Model

Idriss

Sayyed

Osama

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: The most appropriate route for bone marrow-derived mesenchymal stem cell (BM-MSC) transplantation in the management of liver fibrosis remains controversial. This study investigated the therapeutic efficacy of intravenous and intrasplenic BM-MSC transplantation on carbon tetrachloride (CCl₄)-induced rat liver fibrosis. Methods: Fifty rats were divided into 5 groups (n = 10 rats per group): healthy control group, CCl₄ group, CCl₄/ recovery group, CCl₄/BM-MSC intravenous group, and CCl₄/BM-MSC intrasplenic group. BM-MSCs were isolated, labeled with green fluorescent protein (GFP), and injected into fibrotic rats either intravenously or intrasplenically. Gene expression of interleukins (IL-1β and IL-6), interferon (INF)-γ, hepatic growth factor, and the hepatocyte-specific marker cytokeratin 18 was estimated by quantitative real-time reverse transcription-polymerase chain reaction. Vascular endothelial growth factor and connective tissue growth factor was detected by western blot analysis and enzyme-linked immunosorbent assay, respectively. At 2 weeks after intravenous and intrasplenic BM-MSC injections, GFP-positive cells were detected in liver tissue. Results: Both routes achieved a similar enhancement of liver function, which was confirmed by histopathological examination. The intravenous route was more effective than the intrasplenic route in reducing gene expression levels of IL-1β, IL-6, and INF-γ. However, fibrotic changes were still observed in the recovery group. Conclusion: Intravenous BM-MSC injection was an efficient and appropriate route for BM-MSC transplantation for the management of liver fibrosis.

show abstract

Section: Discussionsupporting

confidence: 91%

Treatment Efficiency of Different Routes of Bone Marrow-Derived Mesenchymal Stem Cell Injection in Rat Liver Fibrosis Model

Idriss

Sayyed

Osama

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…2). From those studies multiple mechanisms have been suggested to play a role in in vivo liver amelioration [97], such as: immunomodulation [56,98] (as discussed above); apoptosis of HeSCs [99]; inhibition of HeSC activation and/or their deactivation [76,100]; protective effects on hepatic cells [100][101][102][103] (see above), and restoration or induction of hepatic cell proliferation [76,84,103,104] (Fig. 2).…”

Section: Mechanisms Involved In Msc-mediated Liver Fibrosis/cirrhosismentioning

confidence: 99%

Mesenchymal Stem/Stromal Cells in Liver Fibrosis: Recent Findings, Old/New Caveats and Future Perspectives

Fiore

Mazzolini

Aquino

2015

Stem Cell Rev and Rep

View full text Add to dashboard Cite

Mesenchymal stem/stromal cells (MSCs) are progenitors which share plastic-adherence capacity and cell surface markers but have different properties according to their cell and tissue sources and to culture conditions applied. Many recent publications suggest that MSCs can differentiate into hepatic-like cells, which can be a consequence of either a positive selection of rare in vivo pluripotent cells or of the original plasticity of some cells contributing to MSC cultures. A possible role of MSCs in hereditary transmission of obesity and/or diabetes as well as properties of MSCs regarding immunomodulation, cell fusion and exosome release capacities are discussed according to recent literature. Limitations in methods used to track MSCs in vivo especially in the context of liver cirrhosis are addressed as well as strategies explored to enhance their migratory, survival and proliferation properties, which are known to be relevant for their future clinical use. Current knowledge regarding mechanisms involved in liver cirrhosis amelioration mediated by naïve and genetically modified MSCs as well as the effects of applying preconditioning and combined strategies to improve their therapeutic effects are evaluated. Finally, first reports of GMP guidelines and biosafety issues in MSCs applications are discussed.

show abstract

“…It is widely accepted that BMSCs differentiate into hepatocytes or hepatic-like cells. In the process of chronic liver disease, BMSCs delay the process of liver cirrhosis and prevent the occurrence of HCC [84]. However, a number of studies have shown that BMSCs have the potential to exacerbate the pathogenesis of tumors and cancer metastasis in situ via cell-cell interaction, secretion of cytokines and growth factors [85].…”

Section: Introductionmentioning

confidence: 99%

Expression of cancer stem cell biomarkers as a tool for a correct therapeutic approach to hepatocellular carcinoma

et al. 2015

View full text Add to dashboard Cite

Liver cancer is the fifth most commonly diagnosed malignancy and the second most frequent cause of cancer death in men worldwide. Amongst liver cancers, hepatocellular carcinoma (HCC) represents the major histological subtype and it is one of the most common malignant human tumors worldwide. Research into the molecular biology of hepatocarcinogenesis has identified several biomarkers, which could provide additional informations in order to better understand the biology of HCC. A large number of biomarkers have been shown to have potential predictive significance and a wide variety of molecular markers have been proven to be excellent diagnostic tools for HCC but it is difficult to characterize HCC with a single biomarker. Thus, signatures of a combination of biomarkers may be more valuable for the diagnosis, staging and prognosis of HCC. Specifically, a correlation of HCC-CSCs phenotype to specific hepatic cancer subtypes and to specific clinical and pathological features has not yet been reported in human liver tumors. In this view we will first discuss the possible sources of liver stem cells and their relation with liver cancer development and we will secondly focus on the prognostic significance of clinical and pathological features of HCC.

show abstract

Autologous bone marrow-derived mesenchymal stem cell transplantation promotes liver regeneration after portal vein embolization in cirrhotic rats

Cited by 39 publications

References 67 publications

Treatment Efficiency of Different Routes of Bone Marrow-Derived Mesenchymal Stem Cell Injection in Rat Liver Fibrosis Model

Treatment Efficiency of Different Routes of Bone Marrow-Derived Mesenchymal Stem Cell Injection in Rat Liver Fibrosis Model

Mesenchymal Stem/Stromal Cells in Liver Fibrosis: Recent Findings, Old/New Caveats and Future Perspectives

Expression of cancer stem cell biomarkers as a tool for a correct therapeutic approach to hepatocellular carcinoma

Contact Info

Product

Resources

About